Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Laboratorios Farmaceuticos Rovi EV-to-OCF?
Laboratorios Farmaceuticos RoviLABFF 99 EV-to-OCF is 12.10 as of Aug. 25, 2026, which is 46% below its 10-year median of 22.54. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.89 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 54.13% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's EV-to-OCF or its related term are showing as below:
LABFF'
s EV-to-OCF Range Over the Past 10 Years
Min: -303.74 Med: 22.54 Max: 395.74
Current: 12.06
During the past 13 years, the highest EV-to-OCF of Laboratorios Farmaceuticos Rovi was 395.74. The lowest was -303.74. And the median was 22.54.
LABFF's EV-to-OCF is ranked worse than 54.13% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.77
vs LABFF: 12.06
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Laboratorios Farmaceuticos Rovi's PE Ratio (TTM) for today is calculated as:
Laboratorios Farmaceuticos Rovi's share price for today is $67.17.
Laboratorios Farmaceuticos Rovi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.212.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Laboratorios Farmaceuticos Rovi EV-to-OCF Related Terms
Laboratorios Farmaceuticos Rovi EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's EV-to-OCF falls into.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is $3,570.9 Mil.
Laboratorios Farmaceuticos Rovi's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $295.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a EV-to-OCF of 12.10 as of Aug. 25, 2026. This is 46% below median its historical median of 22.54. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #544 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Laboratorios Farmaceuticos Rovi's EV-to-OCF too high?
Laboratorios Farmaceuticos Rovi's current EV-to-OCF of 12.10 is 46% below median its 10-year median of 22.54. The Drug Manufacturers industry median EV-to-OCF is 10.77. Laboratorios Farmaceuticos Rovi's value of 12.10 is 12.3% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #544 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #544 out of 1005 companies for EV-to-OCF. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median EV-to-OCF is 10.77. Laboratorios Farmaceuticos Rovi's value of 12.10 is 12.3% above this benchmark. While the company's 10-year median is 22.54 vs. the industry median of 10.77, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.77, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current EV-to-OCF of 12.10 is 12.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current EV-to-OCF is 12.10, which is 46% below median its own 10-year median of 22.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.89, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current EV-to-OCF is 12.10, which is 46% below median its 10-year median of 22.54 and 12.3% above the Drug Manufacturers industry median of 10.77. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current EV-to-OCF is 12.10 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued.
The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.89.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.
Key valuation signals for LABFF:
EV-to-OCF: 12.10 (46% below median its 10-year median of 22.54)
GF Value™: $85.89 vs. price of $67.17 (21.8% below fair value)
Industry Position: 12.3% above the Drug Manufacturers median (#544 of 1005)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score
Get the complete analysis for LABFF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
